{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:57:29Z","timestamp":1793912249893,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["401023770"],"award-info":[{"award-number":["401023770"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP2084"],"award-info":[{"award-number":["SPP2084"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bone.2023.116741","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T22:14:02Z","timestamp":1679091242000},"page":"116741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model"],"prefix":"10.1016","volume":"171","author":[{"given":"Lukas Clemens","family":"B\u00f6ckelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Freytag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kristin","family":"Ahlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Maar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gosau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Baranowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116741_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bone.2023.116741_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2016.02.002","article-title":"Disseminated tumor cells and dormancy in prostate cancer metastasis","volume":"40","author":"van der Toom","year":"2016","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.bone.2023.116741_bb0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u201cseed and soil\u201d hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2021.09.037","article-title":"Prostate cancer dormancy and recurrence","volume":"524","author":"Cackowski","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2023.116741_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2023.116741_bb0030","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.2008.17.0563","article-title":"Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer","volume":"27","author":"Weckermann","year":"2009","journal-title":"JCO."},{"key":"10.1016\/j.bone.2023.116741_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.28002","article-title":"Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients","volume":"133","author":"Lilleby","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/bonekey.2014.79","article-title":"Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients","volume":"3","author":"Pantel","year":"2014","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.bone.2023.116741_bb0045","first-page":"1091","article-title":"The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination, cancer","volume":"2","author":"Labelle","year":"2012","journal-title":"Discovery"},{"key":"10.1016\/j.bone.2023.116741_bb0050","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1111\/jcmm.13867","article-title":"Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy","volume":"22","author":"Sai","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bone.2023.116741_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"European Urology"},{"key":"10.1016\/j.bone.2023.116741_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(02)00413-5","article-title":"The role of androgens and the androgen receptor in prostate cancer","volume":"187","author":"Debes","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2023.116741_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.bone.2023.116741_bb0070","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Null null, changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.bone.2023.116741_bb0075","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/cancers12061529","article-title":"Pathophysiology of bone loss in patients with prostate cancer receiving androgen-deprivation therapy and lifestyle modifications for the Management of Bone Health: a comprehensive review","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bone.2023.116741_bb0080","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031252","article-title":"The biology of bone metastasis","volume":"8","author":"Esposito","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bone.2023.116741_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fonc.2020.00293","article-title":"Calcium homeostasis: a potential vicious cycle of bone metastasis in breast cancers","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bone.2023.116741_bb0090","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"JCO."},{"key":"10.1016\/j.bone.2023.116741_bb0095","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (Zoledronic Acid\/Androgen blockade trial on prostate Cancer) study","volume":"33","author":"Ueno","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2023.116741_bb0100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/ERC-14-0199","article-title":"Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone","volume":"21","author":"Ottewell","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0105","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-11-2900","article-title":"Human prostate cancer in a clinically relevant xenograft mouse model: identification of \u03b2(1,6)-branched oligosaccharides as a marker of tumor progression","volume":"18","author":"Lange","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2023.116741_bb0110","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1158\/1078-0432.CCR-13-2308","article-title":"Aberrant presentation of HPA-reactive carbohydrates implies selectin-independent metastasis formation in human prostate cancer","volume":"20","author":"Lange","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2023.116741_bb0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2020.06.025","article-title":"Xenograft-derived mRNA\/miR and protein interaction networks of systemic dissemination in human prostate cancer","volume":"137","author":"Lange","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0120","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm.2338","article-title":"RGB marking facilitates multicolor clonal cell tracking","volume":"17","author":"Weber","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2023.116741_bb0125","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/mt.2008.6","article-title":"A multicolor panel of novel lentiviral \u201cGene ontology\u201d (LeGO) vectors for functional gene analysis","volume":"16","author":"Weber","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bone.2023.116741_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12885-020-07015-9","article-title":"The initial engraftment of tumor cells is critical for the future growth pattern: a mathematical study based on simulations and animal experiments","volume":"20","author":"Hoffmann","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0135","doi-asserted-by":"crossref","first-page":"13986","DOI":"10.1038\/s41598-018-32236-1","article-title":"Differential proteome analysis of human neuroblastoma xenograft primary tumors and matched spontaneous distant metastases","volume":"8","author":"H\u00e4nel","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2023.116741_bb0140","doi-asserted-by":"crossref","first-page":"17535","DOI":"10.1038\/s41598-018-35695-8","article-title":"Development and characterization of a spontaneously metastatic patient-derived xenograft model of human prostate cancer","volume":"8","author":"Lange","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2023.116741_bb0145","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bone.2023.116741_bb0150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.acthis.2009.05.004","article-title":"Comparison of two techniques for the screening of human tumor cells in mouse blood: quantitative real-time polymerase chain reaction (qRT-PCR) versus laser scanning cytometry (LSC)","volume":"112","author":"Nehmann","year":"2010","journal-title":"Acta Histochem."},{"key":"10.1016\/j.bone.2023.116741_bb0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/cancers12020385","article-title":"Modeling spontaneous bone metastasis formation of solid human tumor xenografts in mice","volume":"12","author":"Labitzky","year":"2020","journal-title":"Cancers."},{"key":"10.1016\/j.bone.2023.116741_bb0160","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/jbmr.4043","article-title":"Mice carrying a ubiquitous R235W mutation of wnt1 display a bone-specific phenotype","volume":"35","author":"Yorgan","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116741_bb0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","article-title":"Integrating new discoveries into the \u201cvicious cycle\u201d paradigm of prostate to bone metastases","volume":"33","author":"Cook","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bone.2023.116741_bb0170","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.bone.2023.116741_bb0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/1476-4598-13-244","article-title":"Perforin-dependent direct cytotoxicity in natural killer cells induces considerable knockdown of spontaneous lung metastases and computer modelling-proven tumor cell dormancy in a HT29 human colon cancer xenograft mouse model","volume":"13","author":"Brodbeck","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0180","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/jbmr.2300","article-title":"Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models","volume":"29","author":"Wang","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116741_bb0185","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1158\/0008-5472.CAN-05-0540","article-title":"The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4\u2013Induced invasion in prostate cancer","volume":"65","author":"Miwa","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2023.116741_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bone.2023.116741_bb0195","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41556-018-0236-7","article-title":"Tumour heterogeneity and metastasis at single-cell resolution","volume":"20","author":"Lawson","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bone.2023.116741_bb0200","doi-asserted-by":"crossref","first-page":"11117","DOI":"10.1038\/s41598-019-47308-z","article-title":"Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: vascular perfusion, vasculature density, hypoxic burden and BB2r-targeting efficacy","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2023.116741_bb0205","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate Cancer1","volume":"9","author":"Corey","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2023.116741_bb0210","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2023.116741_bb0215","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","article-title":"Modifying the osteoblastic niche with zoledronic acid in vivo\u2014Potential implications for breast cancer bone metastasis","volume":"66","author":"Haider","year":"2014","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:15:51Z","timestamp":1778940951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"alternative-id":["S8756328223000741"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116741","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116741"}}